Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia

William G. Wierda(The University of Texas MD Anderson Cancer Center), Maher Albitar(Genomic Health (United States)), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Susan Lerner(Molecular Templates (United States)), Deborah A. Thomas(Washington University in St. Louis), Stefan Faderl(Jazz Pharmaceuticals (United States)), Francis J. Giles(National University of Ireland), Marcella M. Johnson(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Amanda Dey(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Kim‐Anh Do(Cancer Research And Biostatistics), Taghi Manshouri(The University of Texas MD Anderson Cancer Center)
British Journal of Haematology
February 1, 2003
10.1046/j.1365-2141.2003.04118.x
Cited by 80

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k